Medtronic Posts Q1 Beat, 2027 Outlook Raise Validates Growth Inflection
MDT shares rise after Q1 beat and raised FY27 growth guidance. Analysts maintain Buy/Outperform ratings, citing broad-based strength.
Medtronic did better than expected this quarter and promised even stronger growth ahead, which makes investors and experts more confident in the company. When a company beats expectations and raises its outlook, it's a signal that the business is running well and the leaders believe good things are coming.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.